Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
38 shown of 7,137 total abstracts
  1. Abstract 98102026-06-05 · 16:15 CT · Hall B1
    Quality of life outcomes with Tagrisso in patients with NSCLC
    L. Paz-Ares, R. Herbst, M. Krop · University of Chicago
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  2. Abstract 95962026-06-01 · 19:30 CT · S406
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-373
    C. Robert, S. Tolaney, E. Winer · Dana-Farber Cancer Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  3. Abstract 95712026-06-04 · 21:45 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-456
    F. Andre, M. Krop, L. Paz-Ares · Vall d'Hebron Institute of Oncology
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  4. Abstract 90322026-06-02 · 15:00 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with NSCLC
    G. Curigliano, R. Herbst, J. Cortes, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  5. Abstract 95552026-06-05 · 19:30 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-380 study)
    H. Borghaei, J. Brahmer · Chinese University of Hong Kong
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  6. Abstract 93302026-06-02 · 13:45 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-486
    L. Paz-Ares, S. Antonia, N. Rizvi, et al. · Memorial Sloan Kettering Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  7. Abstract 94702026-06-03 · 16:45 CT · S100A
    FLAURA-358: Tagrisso (osimertinib) 1L in NSCLC
    G. Curigliano, C. Saura, C. Robert, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  8. Abstract 91322026-06-04 · 15:15 CT · S406
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    G. Curigliano, M. Krop, R. Herbst, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionLung Cancer—Small Cell📄🖼️
  9. Abstract 98722026-06-03 · 15:00 CT · S100A
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-858
    M. Reck, S. Antonia · Mayo Clinic
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  10. Abstract 97052026-06-01 · 14:30 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-827
    J. Cortes, M. Reck · University of Chicago
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  11. Abstract 96122026-06-03 · 19:30 CT · S406
    Quality of life outcomes with Enhertu in patients with NSCLC
    S. Peters, M. Krop · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  12. Abstract 98192026-06-05 · 19:30 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-495
    C. Saura, J. Cortes · Massachusetts General Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  13. Abstract 99272026-06-02 · 19:00 CT · S100A
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-227
    N. Rizvi, H. Borghaei · Princess Margaret Cancer Centre
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  14. Abstract 95092026-06-03 · 13:15 CT · S406
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-16 study)
    A. Spira, E. Winer, S. Peters, et al. · Karolinska Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  15. Abstract 92942026-06-04 · 20:00 CT · E450
    Long-term follow-up of Imfinzi 1L for SCLC: PACIFIC-453
    L. Paz-Ares, M. Krop, J. Cortes, et al. · Chinese University of Hong Kong
    Education SessionLung Cancer—Small Cell📄🖼️
  16. Abstract 91492026-06-04 · 21:30 CT · Hall B1
    Quality of life outcomes with Opdivo in patients with NSCLC
    G. Curigliano, J. Brahmer · Royal Marsden Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  17. Abstract 90682026-06-04 · 14:30 CT · E450
    Long-term follow-up of Keytruda maintenance for SCLC: KEYNOTE-684
    M.C. Garassino, M. Krop · Dana-Farber Cancer Institute
    Education SessionLung Cancer—Small Cell📄🖼️
  18. Abstract 94342026-06-02 · 13:00 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-824
    S. Peters, J. Cortes, M. Reck, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  19. Abstract 92552026-06-05 · 21:45 CT · E450
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-466
    S. Peters, P. Schmid, J. Cortes, et al. · Peter MacCallum Cancer Centre
    Education SessionLung Cancer—Small Cell📄🖼️
  20. Abstract 92512026-06-05 · 13:15 CT · S100A
    Real-world effectiveness of Imfinzi vs standard of care in NSCLC
    J. Cortes, R. Herbst, S. Antonia, et al. · Stanford Cancer Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  21. Abstract 94502026-06-04 · 18:30 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-312 study)
    J. Brahmer, M.C. Garassino, A. Spira, et al. · Royal Marsden Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  22. Abstract 99092026-06-04 · 14:00 CT · E450
    Long-term follow-up of Tecentriq 1L for NSCLC: IMpower-277
    R. Herbst, S. Antonia · Cleveland Clinic
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  23. Abstract 90542026-06-01 · 13:45 CT · E450
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-991 study)
    H. Borghaei, M.C. Garassino, J. Brahmer, et al. · National Cancer Center Japan
    Education SessionLung Cancer—Small Cell📄🖼️
  24. Abstract 91352026-06-05 · 14:30 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-187
    J. Cortes, H. Rugo, S. Peters, et al. · Dana-Farber Cancer Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  25. Abstract 96822026-06-05 · 19:30 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-342 study)
    M. Reck, M. Krop, C. Robert, et al. · Cleveland Clinic
    Education SessionLung Cancer—Small Cell📄🖼️
  26. Abstract 94652026-06-03 · 21:45 CT · S406
    Quality of life outcomes with Imfinzi in patients with NSCLC
    P. Schmid, F. Andre, C. Robert, et al. · Cleveland Clinic
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  27. Abstract 96252026-06-03 · 21:30 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-519 study)
    R. Herbst, S. Antonia, P. Schmid · Royal Marsden Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  28. Abstract 90252026-06-05 · 16:15 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-425 study)
    E. Winer, P. Schmid, C. Robert, et al. · Royal Marsden Hospital
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  29. Abstract 98252026-06-01 · 13:00 CT · E450
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-128
    R. Herbst, E. Winer, T. Mok, et al. · University of Chicago
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  30. Abstract 90032026-06-03 · 20:30 CT · E450
    DESTINY-Breast-580: Enhertu (trastuzumab deruxtecan) 1L in NSCLC
    J. Brahmer, A. Spira, M.C. Garassino · Karolinska Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  31. Abstract 98252026-06-04 · 20:00 CT · S406
    Long-term follow-up of Tecentriq maintenance for NSCLC: IMpower-927
    N. Rizvi, C. Saura, F. Andre, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  32. Abstract 99982026-06-02 · 14:45 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-809 study)
    S. Tolaney, P. Schmid · Stanford Cancer Institute
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  33. Abstract 96732026-06-04 · 16:45 CT · Arie Crown Theater
    Long-term follow-up of Tecentriq neoadjuvant for NSCLC: IMpower-799
    P. Schmid, G. Curigliano, F. Andre, et al. · Johns Hopkins Kimmel Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  34. Abstract 96882026-06-05 · 18:00 CT · Arie Crown Theater
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    M. Reck, J. Brahmer · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  35. Abstract 92252026-06-04 · 20:15 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-848
    H. Rugo, S. Modi · University of Chicago
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  36. Abstract 90782026-06-04 · 21:45 CT · S406
    FLAURA-369: Tagrisso (osimertinib) 3L+ in NSCLC
    C. Saura, L. Paz-Ares, C. Robert, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  37. Abstract 99252026-06-03 · 14:30 CT · S100A
    FLAURA-422: Tagrisso (osimertinib) 3L+ in NSCLC
    S. Antonia, H. Rugo, T. Mok · Johns Hopkins Kimmel Cancer Center
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
  38. Abstract 91652026-06-02 · 19:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-490 study)
    S. Antonia, E. Winer · Chinese University of Hong Kong
    Education SessionLung Cancer—Non-Small Cell Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.